The Swiss food and drinks giant Nestlé is using AI to design nutritionally-tailored products for users of common weight loss drugs, the firm has told Reuters.

Stefan Palzer, chief technical officer at Nestlé, told Reuters that Nestlé scientists are using AI to analyse vast datasets from clinical research and design products that align with the needs of customers on medications such as Novo Nordisk’s Wegovy or Eli Lilly and Company’s Mounjaro.

In presentation materials seen by Reuters, Nestlé outlined how it is seeking to address common side effects of GLP-1 medications through including “Ozempic face”, in which subdermal fat in the face is lost rapidly, through its products.

This includes adding collagen protein to offerings in its wellness brand Vital Products.

“A big ​part of weight loss is that people lose lean muscle mass,” Palzer told Reuters.

“We found a combination of two micronutrients which we industrialized that stimulate the growth of muscle tissue. On ​one hand you provide protein, on the other hand you stimulate the muscle tissue to grow back faster.”

Nestlé is also patenting ingredient combinations that keep diets suppressed after consumers stop taking the medication.

Nestlé has made a series of major AI investments over the past year. In November 2025, it joined Microsoft and Harvard’s Frontier Firm AI Initiative and said it would use the technology to design recipes, improve supply chain efficiency, and making its operations more sustainable.

That month, the firm said all of its 271,000 employees have access to Microsoft’s embedded AI assistant, Copilot Chat, and that 100,000 of its workers now use AI daily. In July 2026, Nestlé also announced a 563 million Swiss Franc ($688 million) investment in a new Nescafé production facility and distribution centre in Thailand which it claims will use AI and smart manufacturing to run efficiently.

---